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Abstract
 
The autoreactive T cells that escape central tolerance and form the peripheral self-reactive rep-
ertoire determine both susceptibility to autoimmune disease and the epitope dominance of a
specific autoantigen. SJL (H-2
 
s
 
) mice are highly susceptible to the induction of experimental
autoimmune encephalomyelitis (EAE) with myelin proteolipid protein (PLP). The two major
encephalitogenic epitopes of PLP (PLP 139–151 and PLP 178–191) bind to IA
 
s
 
 with similar af-
finity; however, the immune response to the PLP 139–151 epitope is always dominant. The
immunodominance of the PLP 139–151 epitope in SJL mice appears to be due to the presence
of expanded numbers of T cells (frequency of 1/20,000 CD4
 
1
 
 cells) reactive to PLP 139–151
in the peripheral repertoire of naive mice. Neither the PLP autoantigen nor infectious environ-
mental agents appear to be responsible for this expanded repertoire, as endogenous PLP 139–
151 reactivity is found in both PLP-deficient and germ-free mice. The high frequency of PLP
139–151-reactive T cells in SJL mice is partly due to lack of thymic deletion to PLP 139–151,
as the DM20 isoform of PLP (which lacks residues 116–150) is more abundantly expressed in
the thymus than full-length PLP. Reexpression of PLP 139–151 in the embryonic thymus re-
sults in a significant reduction of PLP 139–151-reactive precursors in naive mice. Thus, escape
from central tolerance, combined with peripheral expansion by cross-reactive antigen(s), ap-
pears to be responsible for the high frequency of PLP 139–151-reactive T cells.
Key words: autoimmunity • EAE • T cell receptor repertoire • thymic selection • major 
histocompatibility complex and disease
 
Introduction
 
Most autoreactive T cells are deleted in the thymus during
T cell development, reducing both the frequency and affin-
ity of the autoreactive T cells in the peripheral repertoire.
However, not all autoreactive T cells are deleted, and those
cells that do not undergo thymic (central) deletion are
seeded to the peripheral immune compartment and form
the self-reactive repertoire necessary for inducing autoim-
mune diseases. Several mechanisms have been proposed by
which autoreactive T cells can escape thymic deletion. For
myelin antigens, it was initially suggested that sequestration
of myelin antigens behind the blood–brain barrier pre-
cludes central tolerance. The anatomy of the blood–brain
barrier and the lack of lymphatic drainage from the central
nervous system (CNS)
 
1
 
 have been cited to support this hy-
pothesis (1, 2). However, recent data indicates that expres-
sion of myelin basic protein (MBP) and myelin proteolipid
protein (PLP) is not limited to the CNS. Transcripts for
MBP have been detected in both the human (3) and mouse
thymus (4). Moreover, there is now evidence for expres-
sion of MBP protein in the thymi (5) and peripheral lym-
phoid organs (6) of mice. PLP transcripts and protein also
have been reported in human thymus (7), murine thymus
(8), and myocardial cells (9). The discovery of myelin pro-
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Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, experi-
mental autoimmune encephalomyelitis; LDA, limiting dilution analysis;
LNCs, lymph node cells; MBP, myelin basic protein; MOG, oligodendro-
 
cyte glycoprotein; NASE, neuraminidase
 
; 
 
PLP, myelin proteolipid protein. 
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tein expression outside the CNS has led to the reevaluation
of immune tolerance to myelin antigens.
Studies with MBP-deficient (shiverer) mice on the Balb/c
and C3H backgrounds have shown that these mice re-
spond well to MBP, whereas wild-type Balb/c and C3H
mice cannot mount proliferative responses to MBP and are
resistant to MBP-induced experimental autoimmune en-
cephalomyelitis (EAE; 10, 11). In addition, the MBP-reac-
tive T cells from shiverer mice on the Balb/c background
are highly encephalitogenic (11). Collectively, these data
suggest that the expression of MBP results in tolerance to
MBP in wild-type C3H and Balb/c mice. However,
whether this tolerance is mediated in the thymus or periphery
could not be established in these studies. A similar study of
MBP-deficient mice on the B10.PL background has shown
that the immunodominant epitopes of MBP in MBP-defi-
cient mice are different from those in wild-type mice, indi-
cating that there is tolerance to some MBP epitopes. This
study concluded that the MBP-reactive T cells that form the
dominant autoreactive repertoire in the periphery recognize
epitopes that bind with low affinity and form unstable com-
plexes with the self-MHC molecule, whereas T cells that
bind to high-affinity epitopes are tolerized (12).
For PLP, a number of epitopes have been identified that
bind to self-MHC molecules and induce EAE in different
strains of mice. In the SJL (H-2
 
s
 
) strain, EAE can be in-
duced by immunization with PLP 139–151 and PLP 178–
191 (13–15). Both of these epitopes bind with high affinity
to the IA
 
s
 
 MHC class II molecule (15), suggesting that low-
affinity binding of these autoantigenic peptides to self-
MHC molecules (or formation of unstable complexes) may
not be responsible for the escape of PLP-reactive T cells,
which form the autoreactive repertoire in the periphery. In
addition, several lines of evidence demonstrate that of the
two encephalitogenic epitopes of PLP, PLP 139–151 and
178–191, the immune response to PLP 139–151 is always
dominant. First, SJL mice immunized with whole spinal
cord homogenate, which contains multiple myelin anti-
gens, respond selectively to PLP 139–151 (16). Second, if
PLP 139–151-specific cells are tolerized in SJL mice, dis-
ease induction by whole spinal cord homogenate is abro-
gated (17). Lastly, in SJL mice that have recovered from a
mild acute EAE after adoptive transfer of MBP-reactive T
cell lines, the first relapse is concomitant with the develop-
ment of delayed-type hypersensitivity responses to PLP
139–151 (18). The severity of this relapse is consistent with
PLP 139–151 being the dominant encephalitogenic epi-
tope in SJL mice. These results raise two important is-
sues: (a) Why is there such a dominant autoimmune re-
sponse to PLP 139–151 in SJL mice? and (b) How do PLP
139–151-reactive T cells escape thymic deletion even
when the epitope binds to the IA
 
s
 
 class II molecule with
high affinity?
To address these issues, we investigated the mechanism
underlying the dominance of the PLP 139–151 epitope in
SJL mice. The results presented in this study demonstrate
that lymph node cells (LNCs) from unimmunized SJL mice
show a specific proliferative response to the PLP 139–151
 
but not to the PLP 178–191 epitope and that the frequency
of PLP 139–151-reactive T cells in the peripheral reper-
toire is at least 1/20,000 CD4
 
1
 
 T cells. This reactivity is
present in all H-2
 
s
 
 strains but differs in magnitude between
EAE-susceptible (SJL) and EAE-resistant (B10.S) strains.
Using PLP-deficient and germ-free mice, we demonstrate
that selection or expansion of this repertoire is not depen-
dent on PLP expression or cross-reactive infectious agents.
Instead, it appears that failure of negative selection com-
bined with peripheral activation/expansion by a cross-reac-
tive antigen are responsible for the high frequency of PLP
139–151-reactive cells in naive SJL mice.
 
Materials and Methods
 
Animals.
 
Female SJL/J, Balb/c, and C57BL/6 mice were
purchased from The Jackson Laboratory. B10.S mice were ob-
tained from the McLaughlin Research Institute. Balb/s mice are
Balb/c mice into which H-2
 
s
 
 from SJL mice has been bred. Balb/s
mice were obtained from Dr. D. Murphy (New York State
Health Labs, Albany, NY). PLP-deficient mice on the 129 back-
ground were generated by Dr. K. Armin-Nave (University of
Heidelberg, Heidelberg, Germany) (19). PLP-deficient mice
were backcrossed onto both the SJL and Balb/s strains for at least
five generations before being used in experiments. PLP-deficient,
Balb/s, and B10.S mice were bred and maintained at the Eunice
Kennedy Shriver Center. Defined flora SJL mice were purchased
from Harlan Sprague Dawley Inc. Germ-free SJL mice were gen-
erated by Taconic Farms, Inc. from SJL/J stock obtained from
The Jackson Laboratory.
 
Antigens.
 
PLP 139–151 (HSLGKWLGHPDKF) and neur-
aminidase (NASE) 101–120 (EALVRQGLAKVAYVYKPNNT)
were synthesized by Dr. R. Laursen (Boston University, Boston,
MA) on a Milligen model 9050 synthesizer using F-moc chemistry.
PLP 178–191 (NTWTTCQSIAFPSK), MBP 84–104 (VH-
FFKNIVTPRTPPPSQGKGR), and myelin oligodendrocyte gly-
coprotein (MOG) 92–106 (DEGGYTCFFRDHSYQ) were syn-
thesized by Quality Controlled Biochemicals, Inc. Hemagglutinin
(HA) peptide 110–120 (SFERFEIFPKI) was synthesized by Re-
search Genetics. All peptides were HPLC purified, and peptide
identity was confirmed by mass spectroscopy.
 
In Vitro Proliferation Assays.
 
Lymph nodes were harvested from
naive mice. LNCs (4 
 
3
 
 10
 
5
 
 per well) were cultured in serum-free
media (HL-1) supplemented with 
 
l
 
-glutamine (2 mM; BioWhit-
taker Inc.) in triplicate in 96-well round-bottomed plates in the
presence of various concentrations of peptide for 48 h and pulsed
with 1 
 
m
 
Ci of [
 
3
 
H]thymidine per well for the last 16 h. [
 
3
 
H]Thymi-
dine incorporation was determined in a Wallac scintillation counter
(model 1250). For CD44 fractionation assays, CD3
 
1
 
 T cells were
purified from LNCs using CD3 enrichment columns (R & D Sys-
tems, Inc.). CD3
 
1
 
 T cells were then stained with anti-CD44 anti-
body (PharMingen) and separated into CD44
 
hi
 
 and CD44
 
lo
 
 popula-
tions using MACS microbeads (Miltenyi Biotec). Fractionated T
cells (2 
 
3
 
 10
 
5
 
 per well) were incubated with irradiated syngeneic
spleen cells (2 
 
3
 
 10
 
5
 
 per well) in the presence of various concentra-
tions of peptide for 48 h and pulsed with 1 
 
m
 
Ci of [
 
3
 
H]thymidine
per well for the last 16 h. [
 
3
 
H]Thymidine incorporation was deter-
mined as described above.
 
Limiting Dilution Analysis.
 
Limiting dilution analysis (LDA)
was performed on LNCs from naive mice in the presence of 50
 
m
 
g/ml of PLP 139–151 or NASE 101–120 and irradiated synge-
neic spleen cells (5 
 
3
 
 10
 
5
 
 cells per well) in 96-well round-bot- 
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tomed plates. After 72 h, plates were pulsed with 1 
 
m
 
Ci of
[
 
3
 
H]thymidine per well and harvested 16 h later. [
 
3
 
H]Thymidine
incorporation was determined as described above. Wells with
cpms that were three SD over the mean cpm of control wells
(NASE 101–120) were counted as positive. Input cell number
was corrected for percent of CD4
 
1
 
 T cells in the initial LNC
population.
 
Reverse Transcriptase–PCR.
 
Total RNA was extracted from
brains and thymi of SJL mice by homogenization in TRIzol Re-
agent (GIBCO BRL). RNA was then treated with DNaseI to
eliminate contaminating genomic DNA before cDNA synthesis
using SuperScript (GIBCO BRL). First strand cDNA was then
used in reverse transcriptase (RT)-PCR. PLP/DM20 products
were amplified in the presence of 10 mM Tris, pH 9.0, 50 mM
KCl, 1.5 mM MgCl
 
2
 
, 200 
 
m
 
M dNTPs, 300 nM 5
 
9 
 
primer (5
 
9
 
-
GCT CTC ACT GGT ACA GAA-3
 
9
 
), 200 nM 3
 
9
 
 primer (5
 
9
 
-
TAC ATT CTG GCA TCA GCG CAG AGA CTG C-3
 
9
 
), and
2.5 U of Taq polymerase (Promega Corp.) (20). Hot start PCR
was performed: 95
 
8
 
C for 2 min (94
 
8
 
C for 1 min, 55
 
8
 
C for 1 min,
72
 
8
 
C for 1 min) for 40 cycles, with a final extension at 72
 
8
 
C for 5
min. 
 
b
 
-Actin was amplified as above, except that 1.25 U of Taq
polymerase, 200 nM 5
 
9
 
primer (5
 
9
 
-TGG AAT CCT GTG GCA
TCC ATG AAA C-3
 
9
 
), and 200 nM 3
 
9
 
 primer (5
 
9
 
-TAA AAC
GCA GCT CAG TAA CAG TCC G-3
 
9
 
) was used. The cycling
conditions were 94
 
8
 
C for 4 min (94
 
8
 
C for 45 s, 58
 
8
 
C for 1 min,
and 72
 
8
 
C for 1 min) for 25 cycles, with a final extension at 72
 
8
 
C
for 5 min. PCR products were visualized on 1.5% agarose gels.
 
Fetal Tolerization with Ig Chimeras.
 
Ig chimeras with PLP
peptides have been described (21). In brief, IgPLP 139–151 (Ig–
PLP1) is a Balb/c IgG2b carrying PLP 139–151 within the vari-
able region of the H chain. This was done by deleting the CDR3
region and replacing it with the coding sequence for PLP 139–
151. The control Ig, IgCTRL (Ig–W), is the parental Ig. For fe-
tal tolerization experiments, pregnant SJL/J females were in-
jected intravenously with 100 
 
m
 
g of IgPLP 139–151 (Ig–PLP1)
or IgCTRL (Ig–W) on days 16, 17, and 18 of gestation as previ-
ously described (22). Proliferative responses of offspring were an-
alyzed at 8 wk of age.
 
Thymocyte Proliferation Assay.
 
Pregnant mice were tolerized as
described above. Thymocytes were isolated from pups at birth
(day 21) by purification on nylon wool. APCs were obtained
from adult SJL mice. APCs were depleted of T cells by treatment
with anti-CD3 antibody and rabbit complement, passaged over a
dense BSA gradient (Intergen), and irradiated (300 rads) before
use in the assay. Neonatal thymocytes (2 
 
3
 
 10
 
5
 
 cells per well)
were incubated with APCs (5 
 
3
 
 10
 
5
 
 cells per well) and 100 
 
m
 
g/
ml of PLP 139–151 peptide for 3 d. Subsequently, 1 
 
m
 
Ci/well of
[
 
3
 
H] thymidine was added, and the culture was continued for an
additional 14.5 h. Proliferation was measured by counting the in-
corporated [
 
3
 
H]thymidine on a Wallac 1409 beta counter.
 
Results
 
To investigate the mechanism underlying the dominance
of the PLP 139–151 epitope in SJL mice, we first tested the
proliferative responses of LNCs from naive SJL mice to a
panel of myelin antigens known to induce EAE in the SJL
strain: PLP 139–151, PLP 178–191, MOG 92–106, and
MBP 84–104 (13, 15, 23, 24). LNCs from naive SJL mice
proliferated well to PLP 139–151 but not to any of the
other myelin antigens tested (Fig. 1). This suggested that
PLP 139–151-reactive T cells are present in expanded
 
numbers in the peripheral repertoire of naive SJL mice such
that they show a proliferative response in vitro without
prior immunization.
To further analyze this phenomenon, we tested the
proliferative responses of LNCs from mice that are con-
genic at the MHC with SJL, Balb/s, and B10.S but that
differ in their susceptibility to PLP 139–151-induced EAE.
Whereas SJL and Balb/s mice both develop EAE, B10.S
mice are relatively resistant to the development of disease
(25). As shown in Fig. 2, LNCs from naive SJL, Balb/s, and
B10.S mice responded to PLP 139–151 but not to a con-
trol antigen, NASE. The T cell response to PLP 139–151
in Balb/s mice is comparable to that of SJL. Interestingly,
however, the response in B10.S mice, which are resistant
to PLP 139–151-induced EAE (25), is reduced when com-
pared with SJL and Balb/s. We have compared in parallel
the T cell response of LNCs of a number (six to seven) of
individual unimmunized SJL and B10.S mice to PLP 139–
151. The data demonstrate that endogenous reactivity to
PLP 139–151 is significantly reduced (
 
P
 
 , 
 
0.004) in the re-
sistant B10.S mice (data not shown). LNCs taken from na-
ive non-H-2
 
s
 
 (Balb/c and C57BL/6) mice did not exhibit
any proliferative response to the PLP 139–151 peptide, in-
dicating that the proliferation observed in the LNCs of SJL,
Balb/s, and B10.S mice is linked to H-2 and is not due to a
nonspecific mitogenic effect of the PLP 139–151 peptide
used in the assays (Fig. 2). Furthermore, this endogenous
reactivity to PLP 139–151 has been observed with several
batches of PLP 139–151 peptide made by different ven-
dors. Taken together, these data demonstrate that all H-2
 
s
 
strains tested have a relatively high frequency (and/or high
affinity) of PLP 139–151-reactive T cells in the periphery.
There may also be differences in the size and/or affinity of
this repertoire in susceptible versus resistant strains, sup-
porting a functional role for this repertoire in autoimmune
disease. These data suggest that the expanded endogenous
Figure 1. Naive SJL mice show a significant T cell response to PLP
139–151 but not to other myelin antigens. LNCs were harvested from
9-wk-old naive SJL mice and tested in triplicate for reactivity to various
myelin antigens over a dose–response of 0.1–100 mg/ml of peptide.
[3H]Thymidine was added at 48 h, and plates were harvested 16 h later.
The data is shown as mean Dcpm (CPM) of triplicate wells, where
DCPM 5 mean CPM in test wells 2 mean CPM in wells with media
only. An experiment representative of at least four independent experi-
ments is shown. 
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PLP 139–151-reactive repertoire in unimmunized SJL
mice may be responsible for the immunodominance of the
PLP 139–151 epitope in this strain.
 
Frequency of PLP 139–151-reactive T Cells Increases with
Age.
 
To determine the frequency of PLP 139–151-reactive
T cells present in naive SJL mice, we performed LDA.
In adult mice (6 wk of age), the frequency of PLP 139–
151-reactive T cells is 
 
z
 
1/44,000 CD4
 
1
 
 T cells (Table I).
This is significantly higher than the previously reported fre-
quency of 1–2/10
 
6
 
 for T cells specific for MBP or for a for-
eign antigen in the peripheral repertoire of naive animals
(26). When we analyzed the frequency of PLP 139–151-
reactive T cells at 36 wk of age, the frequency was 
 
z
 
1/
19,000 CD4
 
1
 
 T cells, suggesting an increase over time.
This could be due to constant seeding of naive PLP 139–
151-reactive T cells to the periphery or to expansion of
these cells once they have reached the peripheral immune
compartment.
 
PLP 139–151 Reactivity in Memory versus Naive T Cells.
 
To determine whether the endogenous PLP 139–151-reac-
tive T cells observed in naive SJL mice are activated in the
periphery, we tested whether PLP 139–151 reactivity re-
sides in the naive or memory subset of T cells. To do this,
we purified T cells from the lymph nodes of SJL mice and
separated them into CD44
 
hi
 
 (memory) and CD44
 
lo
 
 (naive)
populations. As shown in Fig. 3, PLP 139–151 reactivity is
enriched in the CD44
 
hi
 
 subset, and there was a commensu-
rate decrease in PLP 139–151 reactivity in the CD44
 
lo
 
 pop-
ulation. This indicates that PLP 139–151-reactive T cells
are being stimulated in vivo. As CD44
 
hi
 
 cells have a lower
activation threshold and thus would proliferate more
readily, this raised the possibility that there may not be real
differences in the number of PLP 139–151-reactive cells
that reside in the CD44
 
hi
 
 versus CD44
 
lo
 
 populations. To
Figure 2. Endogenous PLP 139–151-reactive
repertoire in different mouse strains. LNCs from
naive SJL, Balb/s, B10.S (all H-2s), C57Bl/6 (H-2b),
and Balb/c (H-2d) mice were harvested and tested
in triplicate for reactivity to PLP 139–151 and to a
control antigen, NASE, over a dose–response of
0.1–100 mg/ml of peptide. [3H]Thymidine was
added at 48 h, and plates were harvested 16 h later.
The data is shown as mean DCPM of triplicate
wells, where DCPM 5 mean CPM in test wells 2
mean CPM in wells with media only.
Table I. Frequency of PLP 139–151-reactive T Cells in SJL Mice
Age Mean frequency Range
wk
6 1/43,700 1/20,000–1/73,500
36 1/19,100 1/12,000–1/25,600
LDA was performed on LNCs from naive SJL mice with 5 3 105
irradiated syngeneic spleen cells and 50 mg/ml PLP 139–151 or NASE
101–120 in 96-well plates. Input cell number was corrected for percent
of CD4 T cells in the initial LNC population. The results show the
mean of three 36-wk-old and four 6-wk-old mice. The range represents
the lowest and highest frequencies observed in any of the mice.
Figure 3. PLP 139–151 reactivity is enriched in the memory subset.
LNCs from naive SJL mice were harvested. LNCs were then fractionated
into CD31CD44lo and CD31CD44hi populations (as described in Materi-
als and Methods) and tested for a proliferative response to PLP 139–151
and to the control antigen, NASE, over a dose–response of 0.1–100 mg/
ml of peptide. T cells were cultured in triplicate. [3H]Thymidine was
added at 48 h, and plates were harvested 16 h later. The data is shown as
mean DCPM of triplicate wells, where DCPM 5 mean CPM in test wells 2
mean CPM in wells with media only.765 Anderson et al.
address this issue, we undertook precursor frequency analy-
sis to determine whether endogenous PLP 139–151-reac-
tive cells would preferentially reside in the CD44hi population.
Limiting dilution experiments comparing CD41CD44hi
and CD41CD44lo cells confirmed that the frequency of re-
sponding cells was approximately two times higher in the
CD44hi compartment than in the CD44lo compartment
(data not shown). In spite of their high levels of CD44 ex-
pression, these cells do not appear to be differentiated to
any effector phenotype, because when they are activated
with PLP 139–151, they produce low levels of IL-2 but
not IFN-g, IL-4, IL-10, or TNF (data not shown).
Neither PLP Autoantigen nor Infectious Environment Is Re-
quired for Generation of the Endogenous PLP 139–151 Reper-
toire. As the data suggested that PLP 139–151-reactive T
cells are present in high frequency and expand with age,
this raised the question of what is responsible for inducing
and expanding the PLP 139–151-reactive T cell repertoire
in naive SJL mice. Answering this issue is critical, because
autoreactive T cells to MBP, PLP, MOG, and other self-
antigens are also seen in expanded numbers in the peripheral
repertoire of normal humans. PLP itself, cross-reactive self-
antigen, or the infectious environment could be responsible
for the induction and/or expansion of the endogenous PLP
139–151-reactive repertoire. To address these possibilities,
we analyzed PLP-deficient and germ-free SJL mice.
To address whether PLP itself is selecting or expanding
the PLP 139–151-reactive T cells, we analyzed the re-
sponse of LNCs from naive PLP-intact and PLP-deficient
mice to PLP 139–151 peptide. PLP-deficient mice have
been generated by introduction of the neomycin resistance
gene in exon 1 of the genomic sequence of PLP, resulting
in loss of expression for PLP and the DM20 isoform of PLP
(19). These mice have a normal phenotype when they are
young but develop neurological impairment by 16 mo of
age (27). We bred these mice onto both the SJL and Balb/s
backgrounds and analyzed them for the expression of en-
dogenous PLP 139–151 reactivity. Our results demonstrate
that the endogenous PLP 139–151-reactive T cell reper-
toire is intact in PLP-deficient animals (Fig. 4).
To address whether cross-reactive microbial antigens are
responsible for stimulating PLP 139–151-reactive T cells in
SJL mice in vivo, we compared the PLP 139–151 response
in the lymph nodes of naive wild-type, defined flora, and
germ-free SJL mice. The defined flora mice were infected
with only one infectious organism (Proteus mirabilis). Germ-
free mice were rederived by cesarean section and main-
tained under germ-free conditions. As shown in Fig. 5, the
endogenous PLP 139–151-reactive repertoire is detectable
in all three groups of mice. In fact, LNCs from both the
germ-free and defined flora mice have a significantly higher
response to PLP 139–151 when compared with cells from
wild-type SJL mice, P , 0.014 and P , 0.03, respectively.
The responses of LNCs from germ-free and defined flora
mice to Con A, which activates all T cells in an unbiased
manner, were not significantly different from the Con A
response in wild-type SJL (data not shown). The height-
ened response in the defined flora and germ-free SJL mice
may be due to lack of an effect (peripheral tolerance: dele-
tion or anergy) of cross-reactive microbial antigens on PLP
139–151-reactive cells. Taken together, these results sug-
gest that a cross-reactive antigen (or antigens) other than
PLP is responsible for the positive selection of PLP 139–151-
reactive cells and the low-level activation of PLP 139–151-
reactive T cells in the periphery.
Thymic Selection of PLP 139–151-reactive T Cells. The fact
that we detect a significant endogenous response to PLP
139–151 and not to PLP 178–191, both of which bind to
IAs with similar affinity, led us to postulate that there might
be differential negative selection of the repertoires for these
two PLP epitopes in the thymi of SJL mice. The PLP gene
has two isoforms, PLP and DM20. The DM20 form is gen-
erated by alternate splicing of full length PLP message and
lacks residues 116–150, thereby eliminating the PLP 139–
151 epitope, whereas the PLP 178–191 epitope remains in-
tact (Fig. 6 A and reference 28). Previous studies have
demonstrated mRNA and protein expression of PLP and
Figure 4. Endogenous PLP 139–151-reactive repertoire is
present in PLP-deficient mice. LNCs were harvested from
PLP1/1 and PLP2/Y mice on the Balb/s background and
tested in triplicate for reactivity to PLP 139–151 and to a con-
trol antigen, NASE, over a dose–response of 0.1–100 mg/ml
of peptide. [3H]Thymidine was added at 48 h, and plates were
harvested 16 h later. The data is shown as mean DCPM of
triplicate wells, where DCPM 5 mean CPM in test wells 2
mean CPM in wells with media only.
Figure 5. Endogenous PLP
139–151-reactive repertoire is
present in germ-free and defined
flora SJL mice. LNCs were har-
vested from naive wild-type, de-
fined flora, and germ-free SJL
mice and tested in triplicate for
reactivity to PLP 139–151 and to
a control antigen, NASE, over a
dose–response of 0.1–100 mg/ml
of peptide. [3H]Thymidine was
added at 48 h, and plates were
harvested 16 h later. The data is
shown as mean DCPM of tripli-
cate wells, where DCPM 5 mean
CPM in test wells 2 mean CPM
in wells with media only.766 Endogenous T Cell Reactivity to PLP
DM20 in the thymi of humans (7) and PLP in mice (8),
suggesting that PLP may play a role in thymic deletion and
central tolerance. In these studies, the expression of PLP
and DM20 mRNA and protein in the thymi was shown at
a single time point and therefore did not address the ques-
tion of whether both isoforms are always expressed and
whether they are expressed at the same ratios during em-
bryonic thymic development, particularly when TCR rear-
rangements are occurring in the thymus. To address this,
we examined the expression of transcripts for full length
PLP and DM20 in the thymi of SJL mice by RT-PCR at
different ages (starting day 16 fetal to 36 wk of age) and
compared this with the expression of these transcripts in
the brains of the same mice. We used primers that can am-
plify both PLP and DM20 cDNA (20). As previously re-
ported, we amplified both PLP and DM20 from brain
cDNA, and the expression of PLP but not DM20 increased
in the brain with age (Fig. 6 B). In contrast, DM20 was
preferentially amplified from the thymic cDNA, and its ex-
pression was seen as early as day 16 of fetal life. The expres-
sion of the upper PLP band was difficult to detect and was
only seen between 20 and 36 wk of age. The preferential
and early expression of DM20 in the thymi of SJL mice
may explain the inefficient negative selection of PLP 139–
151- but not 178–191-reactive T cells in the thymi of SJL
mice. If low or absent expression of PLP 139–151 in the
thymus is responsible for the lack of negative selection to
PLP 139–151, reexpression of PLP 139–151 in the embry-
onic thymus should result in negative selection and loss of
the endogenous repertoire to PLP 139–151.
Introduction of PLP 139–151 into the Thymi of SJL Mice Leads
to Deletion of the Endogenous PLP 139–151-reactive Repertoire.
Because the lack of mRNA expression for full length PLP
in the thymus during early age suggested that the protein
may not be available to mediate negative selection of PLP
139–151 precursors, we introduced the PLP 139–151
epitope into the embryonic thymi of SJL mice. To do this,
we used an Ig chimera in which the CDR3 region of the
antiarsonate antibody, 91A3, is replaced with the PLP 139–
151 epitope, IgPLP 139–151 (21). When administered to
pregnant SJL mice on days 16, 17, and 18 of gestation, the
chimeric Ig crosses the placental barrier and is expressed in
the thymi of newborn mice, where it can interact with PLP
139–151 but not PLP 178–191 precursors (22). We ana-
lyzed the thymocytes from neonates born of IgPLP 139–
151-treated, control Ig (IgCTRL)-treated, or untreated fe-
males for reactivity to PLP 139–151 to determine whether
IgPLP 139–151 treatment would result in the loss of en-
dogenous PLP 139–151-reactive cells in the thymus itself.
As shown in Fig. 7 A, the thymocytes of neonate SJL mice
born of untreated females exhibit significant reactivity to
PLP 139–151 and not to a control peptide. This confirms
that PLP 139–151-reactive cells are present at detectable
frequencies in the thymocyte population of SJL mice and
excludes the possibility that these cells only become detect-
able after expansion in the periphery. When pregnant fe-
male mice are treated with IgPLP 139–151, PLP 139–151
reactivity is dramatically reduced, as demonstrated by a sig-
nificant decrease in the proliferative response to PLP 139–
151 in the thymocytes of pups born of IgPLP 139–151-
treated mice when compared with pups born of untreated
mice. IgCTRL treatment had no significant effect on PLP
139–151 reactivity in the thymus. This directly shows that
presentation of the PLP 139–151 epitope in the thymus re-
sults in the tolerance of endogenous PLP 139–151-reactive
cells by PLP 139–151. Furthermore, when we analyzed en-
dogenous PLP 139–151 reactivity in adult mice born of
IgPLP 139–151- or IgCTRL-treated females, we found, as
shown in Fig. 7 B, that mice that were exposed to IgPLP
139–151 in utero have an z75% reduction in endogenous
PLP 139–151 reactivity when compared with mice ex-
posed in utero to control Ig. These mice also do not de-
velop significant EAE when immunized with PLP 139–151
peptide at 8–10 wk of age (22). We conclude that the PLP
139–151 epitope is not expressed in the thymi of SJL mice
in a manner that is conducive to negative selection of PLP
139–151-reactive T cells. Therefore, exogenous expression
of PLP 139–151 in utero results in a dramatic reduction in
the precursors of PLP 139–151-reactive cells and a decrease
in the endogenous PLP 139–151-reactive repertoire in
adult mice. The lack of negative selection in the thymus in
concert with expansion in the periphery by a cross-reactive
self-antigen other than PLP results in a high frequency of
PLP 139–151-reactive T cells in this autoimmune-prone
strain.
Discussion
We have shown that a high frequency of PLP 139–151-
reactive T cells in naive mice underlies the susceptibility of
Figure 6. PLP/DM20 expression in the brains and thymi of SJL mice.
(A) Schematic diagram of the PLP/DM20 gene. (B) PLP/DM20 cDNA
was amplified by RT-PCR from brains and thymi of SJL mice of differ-
ent ages using primers that amplify both PLP and DM20 (top row). Am-
plification of b-actin from the same cDNA samples is shown as a control
for quality of the cDNA (bottom row). Embryonic day 16 (lanes 1 and 7),
neonate (lanes 2 and 8), 1 wk (lanes 3 and 9), 9 wk (lane 4), 11 wk (lane
10), 20 wk (lanes 5 and 11), 36 wk (lanes 6 and 12), and double distilled
H20 control (lane 13).767 Anderson et al.
the SJL strain to CNS autoimmunity and explains the
dominance of this epitope in this strain. The high fre-
quency of PLP 139–151-reactive cells is the result of at
least two mechanisms: lack of negative selection in the thy-
mus and expansion in the periphery by a cross-reactive an-
tigen. The presence of PLP 139–151-reactive cells in the
naive T cell repertoire appears to be linked to H-2, as it is
shared among strains of the same MHC haplotype (H-2s)
and not others. Moreover, the size of this repertoire may
correlate with disease susceptibility (SJL and Balb/s strains)
and resistance (B10.S strain), raising the possibility that back-
ground genes may influence this endogenous repertoire.
Role of Self-Antigen in Thymic Selection and Peripheral Ex-
pansion of the Autoreactive Repertoire. The study of MBP-
deficient mice on the B10.PL background has demonstrated
one mechanism for the escape from tolerance of autoreac-
tive cells (10–12). Expression of MBP was shown to result
in tolerance of T cells specific for MBP epitopes that bind
with high affinity to class II molecules and form stable pep-
tide–MHC complexes. Therefore, only those T cells reac-
tive to epitopes that bind weakly to the MHC, i.e., MBP
1–11/I-Au (IC50 of 7.4 mM; reference 29) are found in the
periphery and form the dominant repertoire in the normal
adult mouse (12). In contrast, both PLP 139–151 and PLP
178–191 epitopes bind with high affinity to the I-As class II
molecule, with an IC50 of 40 and 740 nM, respectively (15),
and therefore it is unlikely that this mechanism for escape
from immune tolerance is operative in the PLP/H-2s system.
Furthermore, our observations that SJL mice have a high
frequency of PLP 139–151- but not PLP 178–191-reactive
T cells in the naive repertoire suggests that there is differen-
tial tolerance and/or expansion of PLP 139–151-reactive T
cells in H-2s mice. This prompted us to further examine
the mechanism that may be responsible for escape from im-
mune tolerance and expansion of PLP 139–151-specific
cells. Our data suggests that PLP 139–151-reactive T cells
escape thymic deletion due to differences in the relative
abundance and expression of DM20 (which lacks residues
116–150) versus full length PLP in the thymus. If the
amounts of PLP 139–151 are insufficient to delete PLP
139–151-reactive thymocytes, introduction of the PLP
139–151 epitope into the thymus during embryonic devel-
opment should result in the deletion of PLP 139–151 pre-
cursors and loss of the endogenous PLP 139–151 repertoire.
We demonstrated this by introducing the PLP 139–151
epitope as part of an Ig chimera. This resulted in significant
loss of PLP 139–151-reactive thymocytes in neonate SJL
mice. These animals were also resistant to the development
of EAE with the PLP 139–151 peptide when tested as adults
(22), suggesting that the endogenous PLP 139–151-reac-
tive cells are the precursors of pathogenic cells. Thus, lack
of thymic deletion may be one critical factor leading to the
high precursor frequency of PLP 139–151-reactive cells in
the periphery.
Although lack of negative selection to PLP 139–151 in
the thymus is responsible for increased seeding of precur-
Figure 7. Introduction of the PLP 139–
151 epitope into the thymi of SJL mice
reduces the endogenous PLP 139–151-reac-
tive repertoire. (A) Thymocytes were puri-
fied from neonatal mice that had received
IgPLP 139–151, IgCTRL, or no treatment
in utero and activated by PLP 139–151 or
control peptide (HA) in vitro. Treatment
with IgPLP 139–151 but not IgCTRL or
no treatment abolished PLP 139–151-spe-
cific thymocyte proliferation. (B) LNCs
were harvested from naive 8-wk-old SJL
mice (male and female) that were exposed
in utero to IgPLP 139–151 or IgCTRL.
LNCs were tested in triplicate for reactivity
to PLP 139–151 and to a control antigen,
NASE, over a dose–response of 0.1–100
mg/ml of peptide. [3H]Thymidine was
added at 48 h, and plates were harvested 16 h
later. The data is shown as mean DCPM of
triplicate wells, where DCPM 5 mean
CPM in test wells 2 mean CPM in wells
with media only.768 Endogenous T Cell Reactivity to PLP
sors to the periphery, it is unlikely that this is solely respon-
sible for the high frequency of PLP 139–151-reactive cells
observed in the adult SJL mouse. The fact that reactivity
for these cells is enriched in the CD44hi T cell population
and that the repertoire size for PLP 139–151 increases with
age argues strongly for in vivo expansion of these T cells in
the peripheral immune compartment. The recent descrip-
tion of CD44 upregulation on CD41 cells transferred into
lymphopenic mice (30, 31) suggests that CD44 may be a
marker for cells that have undergone one or two divisions in
the periphery but have not developed an effector phenotype.
This is consistent with our finding that the relative frequency
of reactive cells is higher in the CD44hi compartment but
that we do not detect effector cytokines from bulk cultures.
It implies that even in mice with a full complement of
lymphocytes, naive cells of some specificities can divide in
the periphery. As neither PLP-deficient nor germ-free mice
lose the endogenous PLP 139–151-reactive repertoire, we
conclude that neither the PLP autoantigen nor the infectious
environment are necessary for the positive selection or the
peripheral activation/expansion of this repertoire. PLP 139–
151-reactive T cells are most likely positively selected by
cross-reactive self-antigen(s). Whether this same antigen or
antigens present in diet are responsible for the expansion of
these cells in the periphery remains to be seen.
Association of MHC Class II with Autoimmunity. One
important implication of this study is that it provides another
explanation for the common finding of MHC class II associ-
ations with specific autoimmune diseases. One hypothesis for
the association of autoimmune disease with particular MHC
haplotypes is simply that only certain MHC molecules can
bind and present self-peptides. A second hypothesis is that
some MHC molecules (e.g., IAg7) are globally poor at medi-
ating negative selection, leading to a peripheral T cell reper-
toire biased toward self-reactivity (32, 33).
We have now shown that cells with pathogenic potential
may arise in large numbers and in a peptide-specific/class
II–associated fashion. Furthermore, our demonstration that
such cells arise in PLP-deficient mice suggests that the au-
toantigen is not required for the positive selection of these
cells. Rather, the IAs molecule presenting other cross-reac-
tive antigens selects a very high frequency of PLP 139–
151-reactive T cells that further expand in the periphery.
As we observe the expanded repertoire to PLP 139–151
but not to other myelin antigens, this indicates that this is
antigen specific and not a global effect of IAs due to loose
peptide binding, as has been proposed for IAg7 (32, 33).
Thus, our results imply that H-2s–bearing mice, because of
the inherent ability of IAs to expand PLP 139–151-reactive
cells, will be more susceptible to CNS autoimmune disease
and that PLP 139–151 will be the immunodominant
epitope for disease induction. These data provide a cellular
basis for the previous observations made in SJL mice that
the PLP 139–151 epitope is the most dominant encephali-
togenic epitope for EAE induction and for the induction of
tolerance (16, 17).
Effects of Environmental Microflora on the Autoreactive Reper-
toire. We had expected that the infectious environment
might be responsible for the expanded PLP 139–151-reac-
tive repertoire in unimmunized mice. Our finding that germ-
free mice have a higher (and not lower) frequency of PLP
139–151-reactive cells than wild-type controls is consistent
with the observation that NOD mice develop diabetes with
higher frequency when they are maintained in clean animal
facilities (34). The higher frequency of PLP 139–151-reac-
tive T cells in germ-free SJL mice could be due to the
elimination of competing T cell specificities, which allows
for further expansion of PLP 139–151-reactive cells in the
periphery. Alternatively, cross-reactive microbial antigens
may be inducing peripheral tolerance of some of the PLP
139–151-specific T cells. Although to date no germ-free SJL
mice have developed spontaneous disease, with a larger
pool of circulating autoantigen-specific cells they may have
a lower threshold for disease induction. Our observation is
different from that of Goverman et al., who showed that
mice with a TCR transgene specific for MBP Ac1–11 de-
velop more disease in dirty facilities (35). This difference
may be due to the differences in affinity of MBP and PLP
epitopes for their respective restriction elements, which
consequently affects the selection of their respective T cell
repertoires. Alternatively, the differences in the two sys-
tems may reflect a differential balance between factors that
predispose toward disease and factors that initiate disease.
Nonetheless, the data presented here show a significant dif-
ference in the selection and basis for the epitope domi-
nance of MBP and PLP.
Regulation of Autoreactive Cells in the Periphery. As SJL mice
have a very high frequency (at least 1/20,000 CD41 T
cells) of PLP 139–151-reactive T cells in the naive reper-
toire, the LNCs from unimmunized mice show a specific
and significant proliferative response to PLP 139–151. This
measurement of frequency by LDA is likely to be an un-
derestimate; however, at the time of this writing, more
sensitive techniques to measure frequency of PLP 139–
151-specific cells such as PLP 139–151/IAs tetramers are
unavailable. Two previous studies using in vitro prolifera-
tive assays have also suggested that there may be a higher
precursor frequency of PLP 139–151-reactive T cells in the
peripheral repertoire of SJL mice (36, 37), thus supporting
the data presented here. Interestingly, by determining the
precursor frequency of PLP 139–151-reactive T cells in the
immune repertoire of SJL mice, the studies of Miller et al.
(37) also reported a precursor frequency of 1/20,000, an es-
timate similar to that which we have made for the endoge-
nous PLP 139–151-reactive repertoire in naive SJL mice.
These results are reminiscent of data obtained with normal
human volunteers, where it has been shown that PBMCs
from healthy individuals can respond to several myelin an-
tigens, including PLP and MBP (38). What induces this au-
toreactive antimyelin repertoire and what its function may
be in the induction or regulation of autoimmunity has been
debated. Our observation that unimmunized SJL mice
show a specific proliferative response to PLP 139–151 pro-
vided us with a unique opportunity to address many of
these issues. As shown by our results, neither the autoanti-
gen nor the infectious environment is necessary for the ex-769 Anderson et al.
panded PLP 139–151-reactive repertoire to arise in unim-
munized SJL mice. So why don’t all normal individuals
bearing an expanded autoreactive repertoire and normal
SJL mice develop spontaneous disease? We believe that ei-
ther these cells are not activated strongly enough to differ-
entiate into a pathogenic phenotype, or these cells are kept
under check by other endogenous regulatory mechanisms
that inhibit/control the development of spontaneous au-
toimmunity.
In summary, we have found that the predisposition of
H-2s strains toward CNS autoimmunity is partly due to the
very high frequency of autoreactive T cells specific for a
known encephalitogenic epitope of PLP present in naive
mice. This high frequency is the result of at least two
mechanisms: lack of negative selection in the thymus and
further expansion by cross-reactive antigen(s) in the pe-
riphery. In contrast to MBP or other self-antigens, the
mechanism by which PLP-reactive T cells escape thymic
tolerance and expand in the periphery is quite different.
Thus, the mechanisms that underlie epitope dominance
and susceptibility to autoimmune disease may vary depend-
ing on the antigen involved and the genetic background of
the individual. Moreover, we have described for the first
time a significant T cell reactivity to a CNS autoantigen in
unprimed mice of a defined MHC haplotype. Yet these
mice do not develop spontaneous autoimmune disease. We
can now use this model to explore the peripheral mecha-
nisms that prevent these T cells from becoming pathogenic
in vivo. In doing so, we now have the opportunity to bet-
ter understand what mechanisms regulate the autoreactive
T cells present in normal, healthy individuals with defined
disease-associated MHC haplotypes.
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